Bence Jones myeloma


Also found in: Wikipedia.

Bence Jones my·e·lo·ma

(bents jōnz),
multiple myeloma in which the malignant plasma cells excrete only light chains of one type (either κ or λ); lytic bone lesions occur in about 60% of the cases, and light chains (Bence Jones protein) occur in the urine; amyloidosis and severe renal failure are more common than in multiple myeloma.
[Henry Bence Jones]

Bence Jones,

Henry, English physician, 1814-1873.
Bence Jones albumin
Bence Jones cylinders - slightly irregular, relatively smooth, rod-shaped or cylindroid bodies of fairly tenacious, viscid proteinaceous material in the fluid of the seminal vesicles.
Bence Jones myeloma - multiple myeloma in which the malignant plasma cells excrete only light chains of one type (either kappa or lambda). Synonym(s): L-chain disease; L-chain myeloma
Bence Jones proteins - proteins with unusual thermosolubility found in the urine of patients with multiple myeloma, consisting of monoclonal immunoglobulin light chains.
Bence Jones reaction - the classic means of identifying Bence Jones protein.
Bence Jones test
References in periodicals archive ?
Serum test for assessment of patients with Bence Jones myeloma.
3) presented data showing that 224 of 224 patients with Bence Jones myeloma could be identified based on abnormal serum concentrations of FLCs at presentation, without the requirement for urine testing.
However, current data are sufficiently compelling that FLC assays are used routinely in many centers worldwide for diagnosis and monitoring of AL amyloidosis, nonsecretory myeloma, and Bence Jones myeloma.
However, the concentrations typically are quite low in patients with Bence Jones myeloma, particularly when normal bone marrow function is suppressed.
1) (3), and have since extended the measurements to 224 patients presenting with Bence Jones myeloma.
Testing for Bence Jones myeloma and other light chain diseases is by serum immunofixation or urine tests, none of which is ideal.
Development of serum free light chain immunoassays for the detection and monitoring of patients with Bence Jones myeloma [Abstract].
Nine samples were from eight patients with Bence Jones myeloma.
Optimal discrimination between Bence Jones myeloma and other samples lacking MCs occurred at a cutoff of 0.
In conclusion, mathematical algorithms for the analysis of the absorbance curve produced by CE of serum samples could accurately identify 99% of samples with MCs as well as most sera from patients with Bence Jones myeloma, and they can mathematically define criteria for oligoclonality.